Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1/PHASE2
33 participants
INTERVENTIONAL
2025-10-01
2028-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
NCT01931787
Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00077311
Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00002656
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
NCT01719861
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
NCT01737502
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Design and Technical Considerations This is an open-label, multicenter, seamless Phase Ib/II trial. The design integrates a dose-finding phase followed by an efficacy expansion phase to efficiently evaluate both safety and preliminary activity.
Phase Ib (Dose Escalation): Utilizes a standard 3+3 design to determine the Recommended Phase II Dose (RP2D). The starting dose is 20 mg orally once weekly, with planned escalation to 40 mg and 60 mg. The RP2D will be defined as the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity (DLT) during the first 21-day cycle. Pharmacokinetic profiling will be performed to characterize exposure at each dose level.
Phase II (Expansion Cohort): Aims to estimate the objective response rate (ORR) at the RP2D. The study employs a Simon's two-stage minimax design to test the null hypothesis that the true ORR is ≤10% against an alternative of ≥30%, with 90% power and a one-sided alpha of 0.05. This design allows for early termination for futility.
Biomarker Strategy: The protocol incorporates a comprehensive exploratory biomarker plan. This includes correlative analyses of DRD2 expression in archival tumor tissue, serial monitoring of cell-free DNA (cfDNA) for dynamic changes in tumor burden, and assessment of metabolic response via FDG-PET imaging to elucidate potential biomarkers of response and resistance.
Safety Monitoring Focus Given penfluridol's known safety profile from psychiatric use, the protocol institutes enhanced, protocol-specified monitoring for specific risks. This includes regular assessments for extrapyramidal symptoms (using the RSESE scale) and rigorous cardiac monitoring (serial ECGs for QTc interval assessment) beyond standard CTCAE reporting. An independent Data Monitoring Committee (IDMC) will review accumulating safety and efficacy data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
* Cervical small-cell carcinoma accounts for \<2 % of all cervical cancers, and third-/later-line SCLC represents \<5 % of lung-cancer cases.
* A randomized study would require prohibitively large sample sizes and prolong accrual beyond the 3-year funding window.
Absence of an established active comparator
* Historical controls (retrospective cohorts) show ORR ≤ 12-18 % and median PFS ≤ 2.5 months in ≥3-line therapy.
* No standard-of-care regimen is approved after ≥2 prior systemic treatments, making a placebo or active-control arm ethically questionable.
Signal-seeking objective
* The primary goal of this first-in-class oncology application is to define the recommended Phase II dose (RP2D) and to estimate preliminary efficacy signals (ORR), not to demonstrate superiority.
* A single-arm design with an explicit Simon two-stage rule (H0: ORR ≤ 10 % vs. H1: ≥15 %) provides the most efficient path to accept or reject further development with ≤33 patients.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer
Intervention: Penfluridol, an oral antipsychotic drug, is used as monotherapy. It targets DRD2, inhibits glycolysis, and induces apoptosis.
Dosing Schedule:
Phase Ib: 3+3 dose-escalation design. Initial dose 20 mg weekly, escalating to 40 mg, then 60 mg until recommended Phase II dose (RP2D) is determined based on 21-day DLT assessment.
Phase II: Expansion cohort at RP2D to further evaluate safety and estimate ORR. Duration: Treatment continues until progression, unacceptable toxicity, withdrawal, or investigator decision.
Monitoring: Regular AE/SAE monitoring using NCI-CTCAE v5.0. Assessments include weekly vital signs, biweekly blood tests, and ECGs every 2 weeks. Tumor response evaluated by RECIST 1.1 criteria with imaging every 2-3 cycles.
Dose Modification: Adjustments made for EPS, QTc prolongation, and proteinuria. Rationale for Single-Arm Design: Chosen due to the ultra-rare patient population and lack of established comparators. Efficient for determining RP2D and ORR.
Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer
Intervention: Penfluridol, an oral antipsychotic drug, is used as monotherapy. It targets DRD2, inhibits glycolysis, and induces apoptosis.
Dosing Schedule:
Phase Ib: 3+3 dose-escalation design. Initial dose 20 mg weekly, escalating to 40 mg, then 60 mg until recommended Phase II dose (RP2D) is determined based on 21-day DLT assessment.
Phase II: Expansion cohort at RP2D to further evaluate safety and estimate ORR. Duration: Treatment continues until progression, unacceptable toxicity, withdrawal, or investigator decision.
Monitoring: Regular AE/SAE monitoring using NCI-CTCAE v5.0. Assessments include weekly vital signs, biweekly blood tests, and ECGs every 2 weeks. Tumor response evaluated by RECIST 1.1 criteria with imaging every 2-3 cycles.
Dose Modification: Adjustments made for EPS, QTc prolongation, and proteinuria. Rationale for Single-Arm Design: Chosen due to the ultra-rare patient population and lack of established comparators. Efficient for determining RP2D and ORR.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer
Intervention: Penfluridol, an oral antipsychotic drug, is used as monotherapy. It targets DRD2, inhibits glycolysis, and induces apoptosis.
Dosing Schedule:
Phase Ib: 3+3 dose-escalation design. Initial dose 20 mg weekly, escalating to 40 mg, then 60 mg until recommended Phase II dose (RP2D) is determined based on 21-day DLT assessment.
Phase II: Expansion cohort at RP2D to further evaluate safety and estimate ORR. Duration: Treatment continues until progression, unacceptable toxicity, withdrawal, or investigator decision.
Monitoring: Regular AE/SAE monitoring using NCI-CTCAE v5.0. Assessments include weekly vital signs, biweekly blood tests, and ECGs every 2 weeks. Tumor response evaluated by RECIST 1.1 criteria with imaging every 2-3 cycles.
Dose Modification: Adjustments made for EPS, QTc prolongation, and proteinuria. Rationale for Single-Arm Design: Chosen due to the ultra-rare patient population and lack of established comparators. Efficient for determining RP2D and ORR.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically or cytologically confirmed small-cell carcinoma of the lung or cervix that is not curable by surgery or radiochemotherapy.
3. Have received at least two prior systemic treatment regimens, including etoposide and platinum-based chemotherapy, and have experienced disease progression.
4. No receipt of investigational or approved cytotoxic chemotherapy within 28 days before enrollment; no receipt of alkylating agents within 42 days before enrollment; no receipt of investigational or approved targeted therapy within 28 days or 5 half-lives before enrollment (whichever is shorter, but not less than 14 days); no radiotherapy within 14 days before enrollment.
5. Presence of measurable disease according to RECIST 1.1 criteria; measurable lesions are defined as lesions that can be accurately measured in at least one dimension (longest diameter ≥10 mm on CT or MRI scans, and lymph nodes with short-axis diameter ≥15 mm).
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7. Expected survival of ≥12 weeks.
8. Recovery of prior anticancer treatment toxicities to ≤Grade 1 (except for alopecia, pigmentation, or other toxicities deemed non-safety risks by the investigator); for irreversible toxicities that are not expected to worsen with study drug administration (e.g., hearing loss), inclusion may be considered after consultation with the medical monitor. Recovery of peripheral neuropathy to ≤Grade 2 after prior use of cisplatin or etoposide may be considered for inclusion after consultation with the medical monitor. For late toxicities caused by radiotherapy that cannot be recovered, inclusion may be considered after consultation with the medical monitor.
9. Laboratory tests: Absolute neutrophil count ≥1.5×10⁹/L; platelets ≥75×10⁹/L; hemoglobin ≥90 g/L; serum creatinine ≤1.5 times the upper limit of normal (ULN); urine protein \<2+ or 24-hour urine protein \<1.0 g; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times ULN (or ≤5 times ULN in the presence of liver metastasis); total bilirubin ≤1.5 times ULN; albumin ≥28 g/L; coagulation function: prothrombin time (PT) and international normalized ratio (INR) ≤1.5×ULN.
10. Female subjects with negative urine or blood HCG (except for menopausal and hysterectomy cases); sexually active female subjects and their partners must agree to use effective contraception (e.g., combined hormonal contraception, intrauterine device, bilateral tubal ligation, vasectomy, abstinence) during the study and for 6 months after the last dose.
11. Availability of tumor specimens (paraffin-embedded blocks or frozen tissue) from prior resection or biopsy sufficient for pharmacodynamic assays (≥3 slides for immunohistochemistry IHC) (mandatory for dose-expansion cohort patients only).
12. Ability to understand the study and voluntary consent to participate in the trial by the patient or their legal representative, with signed informed consent.
Exclusion Criteria
2. Concurrent enrollment in another clinical trial, unless it is an observational, non-interventional study or the follow-up period of an interventional study.
3. Known hypersensitivity to any component of penfluridol or similar compounds with comparable chemical or biological properties.
4. Prior exposure to penfluridol.
5. Known presence of leptomeningeal metastasis, spinal cord compression, leptomeningeal disease, or active brain metastases. However, patients with asymptomatic brain metastases (no neurological deficits, seizures, or other typical symptoms and signs of central nervous system metastasis; no requirement for corticosteroids) or those who have been treated and are stable on imaging for at least 4 weeks before study treatment (with no new or enlarged brain metastases) and have discontinued systemic corticosteroids and anticonvulsant medications for at least 2 weeks may be included.
6. Uncontrolled comorbid conditions, including but not limited to persistent or active infections or psychiatric/social conditions that would limit compliance with study requirements.
7. Positive for human immunodeficiency virus (HIV) on combination antiretroviral therapy.
8. Cardiovascular history or comorbidities: Known history of arrhythmias (including atrial fibrillation, tachycardia, or bradycardia), except for benign ventricular premature beats; history of CHF, MI, or stroke within the past 3 months.
9. History of seizure within the past 3 months.
10. Gastrointestinal dysfunction or disease that may significantly alter the absorption of penfluridol (e.g., uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
11. Known history of allogeneic organ transplant or allogeneic hematopoietic stem cell transplant.
12. Uncontrolled severe medical conditions that, in the opinion of the investigator, would affect the patient's ability to receive the study treatment, such as severe internal medicine conditions, including hepatic or renal insufficiency, severe cardiovascular disease, cerebrovascular disease, uncontrolled diabetes, or uncontrolled infections.
13. Pregnant or breastfeeding women; sexually active female subjects unwilling to use contraception.
14. Presence of symptomatic or unstable pleural effusion, ascites, or pericardial effusion requiring repeated drainage.
15. Patients deemed unsuitable for the study by the investigator.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peng Wu, PhD
Role: PRINCIPAL_INVESTIGATOR
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UHCT250646
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.